Single-pharmacophore libraries, affinity-based screening, and outsourced discovery services are driving adoption as pharmaceutical and biotech companies seek broader chemical search spaces

ROCKVILLE, MD — September 17, 2026 — The global DNA encoded library market is projected to increase from USD 1.8 billion in 2026 to USD 5.9 billion by 2036, expanding at a 12.7% CAGR, according to Fact.MR. The market reached USD 1.6 billion in 2025, as pharmaceutical companies, discovery-focused contract research organizations, biotechnology sponsors, and academic screening groups increased use of DNA encoded library platforms for early-stage drug discovery.

The market is expected to create an absolute opportunity of USD 4.1 billion between 2026 and 2036. Demand is being supported by the need to search larger chemical spaces, identify potential hits earlier in the discovery process, and reduce the time required to evaluate extensive compound collections.

Get detailed market forecasts, competitive benchmarking, and stem cell industry insights:https://www.factmr.com/connectus/sample?flag=S&rep_id=15730

Single-Pharmacophore Libraries Account for 41.3% Share

Single-pharmacophore libraries are projected to account for 41.3% of the DNA encoded library market in 2026, making them the leading library type. Their focused chemical diversity allows researchers to screen compounds against defined targets while maintaining relevance to the biological question under investigation.

By application, drug discovery is expected to hold 33.3% share in 2026. DNA encoded libraries are particularly relevant during early hit identification and lead-generation activities, before larger investments are made in conventional synthesis and medicinal chemistry.

Pharmaceutical companies are projected to account for 36.0% of market demand in 2026, reflecting their target portfolios, screening budgets, and ability to conduct follow-up chemistry after identifying potential hits.

By screening method, affinity-based screening is forecast to hold 46.5% share in 2026. The method aligns with the core DNA encoded library workflow, in which target binding is followed by sequencing and subsequent hit confirmation.

Oncology Represents 34.4% of Therapeutic Area Demand

Oncology is expected to account for 34.4% of the market in 2026, making it the leading therapeutic area. Cancer drug discovery programs often require broad chemical exploration, particularly when research teams are investigating difficult or previously underexploited targets.

The technology also has applications across neurological, infectious, cardiovascular, metabolic, autoimmune, and rare diseases. Broader use of DNA encoded libraries can expand as sponsors seek screening approaches capable of evaluating extensive chemical diversity before committing to conventional medicinal chemistry programs.

Faster Hit Identification Supports Market Expansion

The need to improve early drug discovery productivity remains a principal factor supporting DNA encoded library adoption. Conventional compound-by-compound screening can require substantial resources, whereas encoded libraries allow researchers to evaluate large collections within a structured screening workflow.

Pharmaceutical companies are an important source of demand because they maintain multiple discovery programs and have the resources to conduct follow-up validation and chemistry. Biotechnology companies and smaller research groups can also access DEL capabilities through specialized CROs, reducing the need to build complete in-house infrastructure.

Integrated services represent another opportunity. Providers combining library access with sequencing, data analysis, hit confirmation, and medicinal chemistry can help sponsors move from initial screening results toward validated compounds.

“DEL demand depends on what happens after the screen. Sponsors want chemical diversity, but they also want validated hits, clean data and a credible path from sequence output to follow-up chemistry,” said Shambhu Nath Jha, Sr. Consultant at Fact.MR.

Hit Validation Remains a Key Challenge

DNA encoded library screening does not eliminate the need for extensive validation. False positives and weak hit confirmation can reduce confidence in screening results and increase the resources required to determine whether an encoded hit can translate into a viable conventional compound.

Specialist assay requirements represent another constraint. Target preparation, assay design, sequencing, and data interpretation require technical expertise, particularly for difficult biological targets.

Follow-up chemistry can also create challenges when an encoded hit does not translate cleanly into a conventional compound. Sponsors therefore increasingly evaluate not only library size but also the provider's ability to support hit confirmation and downstream chemistry.

These challenges create opportunities for integrated DEL providers and CROs that can combine screening, sequencing, data analysis, and medicinal chemistry capabilities within a coordinated workflow.

South Korea Records 13.7% CAGR

The South Korea DNA encoded library market is projected to expand at a 13.7% CAGR from 2026 to 2036, compared with the global CAGR of 12.7%. Local biopharmaceutical research activity, screening support, sequencing capabilities, and CRO participation are identified as factors influencing adoption.

The United States is projected to grow at 13.2% CAGR, supported by large pharmaceutical and biotechnology pipelines and recurring demand for discovery services. The United Kingdom is forecast to expand at 13.1% CAGR, with drug-discovery clusters and university-linked screening activity contributing to market development.

Australia is projected to record a 12.7% CAGR, while Germany, Canada, and Japan are expected to grow at 12.4%, 12.2%, and 11.7%, respectively. Country-level differences reflect biopharmaceutical R&D intensity, CRO capacity, screening infrastructure, and access to validated workflows.

Competitive Landscape

The DNA encoded library market includes specialized providers alongside pharmaceutical companies involved in DEL research and discovery programs.

Fact.MR identifies X-Chem, Inc., WuXi AppTec, HitGen Inc., and Vipergen A/S among the named DEL providers. Novartis AG, AstraZeneca PLC, GSK plc, and Pfizer Inc. are also profiled among pharmaceutical companies active in DEL research or related consortium activity.

Competition is shaped by library quality, assay controls, sequencing accuracy, hit confirmation, intellectual property terms, and medicinal chemistry support. Providers that connect screening results with downstream validation and chemistry services are addressing a broader portion of the discovery workflow.

Unlock Actionable Insights from the Complete Report: https://www.factmr.com/report/dna-encoded-library-market

Report Scope

The Fact.MR DNA Encoded Library Market report covers DNA encoded library platforms, screening services, and related discovery workflows used to identify small-molecule hits for pharmaceutical and biotechnology research.

The study analyzes the market by library type, application, end user, screening method, therapeutic area, and region. Library types include single-pharmacophore libraries, peptide libraries, small-molecule libraries, dual-pharmacophore libraries, macrocycle libraries, cyclic peptide libraries, DNA-templated libraries, and custom DEL libraries.

Applications include drug discovery, hit identification, lead optimization, target identification, protein target screening, receptor screening, academic research, chemical biology, genomics research, diagnostic research, and agricultural biotechnology.

End users include pharmaceutical companies, biotechnology companies, contract research organizations, discovery CROs, preclinical CROs, and academic and research institutes. The geographic scope covers North America, Latin America, Europe, East Asia, South Asia and Oceania, and the Middle East and Africa.

Explore More Related Studies Published by Fact.MR Research:

Artificial Intelligence in Life Sciences Market- https://www.factmr.com/report/artificial-intelligence-in-life-sciences-market

Lumbar Spine Cages Market- https://www.factmr.com/report/lumbar-spine-cages-market

Medical and Pharmaceutical Dynamic Sealing Solutions Market- https://www.factmr.com/report/medical-and-pharmaceutical-dynamic-sealing-solutions-market

Medical Device CDMO Market- https://www.factmr.com/report/medical-device-cdmo-market

Veterinary Sterilization Container Market- https://www.factmr.com/report/veterinary-sterilization-container-market

About Fact.MR

Fact.MR is a market research and consulting firm providing syndicated research, customized research, investment research, and market intelligence across a broad range of industries. Its research coverage includes healthcare, pharmaceuticals, biotechnology, consumer products, chemicals and materials, technology, industrial goods, food and beverage, packaging, and other major sectors.

Fact.MR provides market intelligence designed to help organizations understand market dynamics, emerging opportunities, competitive developments, and changing industry requirements.

Media Contact

Fact.MR
Email: [email protected]
Phone: +1 (628) 251-1583
Website: www.factmr.com